Advertisement

Clinical Rheumatology

, Volume 27, Issue 3, pp 281–287 | Cite as

Statin treatment for rheumatoid arthritis: a promising novel indication

  • Kosmas I. ParaskevasEmail author
Review Article

Abstract

The results of several cross-sectional trials suggest that patients with rheumatoid arthritis (RA) have increased vascular risk and cardiovascular mortality. It was demonstrated that inflammation plays a pivotal role in the pathogenesis of both RA and atherosclerosis. This association may explain the high incidence of cardiovascular disease in RA patients. A number of recent studies show that routine statin use in patients with RA offers considerable advantages. Statin treatment has been supported to exert a beneficial effect on disease activity, swollen joint count, endothelial dysfunction, and arterial stiffness in RA patients. These improvements are coupled with a mild to moderate improvement in plasma markers of inflammation, such as C-reactive protein and erythrocyte sedimentation rate. Statins have a satisfactory safety profile with relatively few adverse effects. In the absence of side effects and contraindications, it may be reasonable to consider statin use in selected cases, particularly in patients with a long history of active RA who are at increased cardiovascular risk.

Keywords

C-reactive protein Indication Rheumatoid arthritis Statins Treatment 

References

  1. 1.
    Walker JG, Littlejohn GO (2006) Measuring quality of life in rheumatic conditions. Clin Rheumatol 26:671–673PubMedCrossRefGoogle Scholar
  2. 2.
    Palkonyai E, Kolarz G, Kopp M et al (2007) Depressive symptoms in early rheumatoid arthritis: a comparative longitudinal study. Clin Rheumatol 26:753–758PubMedCrossRefGoogle Scholar
  3. 3.
    Isik A, Koca SS, Ozturk A, Mermi O (2007) Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 26:872–878PubMedCrossRefGoogle Scholar
  4. 4.
    Birtane M, Uzunca K, Tastekin N, Tuna H (2007) The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis using SF-36 Health Survey. Clin Rheumatol 26:679–684PubMedCrossRefGoogle Scholar
  5. 5.
    Taal E, Bobietinska E, Lloyd J (2006) Successfully living with chronic arthritis. The role of the allied health professionals. Clin Rheumatol 25:189–197PubMedCrossRefGoogle Scholar
  6. 6.
    Brooks PM (2006) The burden of musculoskeletal disease—a global perspective. Clin Rheumatol 25:778–781PubMedCrossRefGoogle Scholar
  7. 7.
    Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25:1776–1785PubMedCrossRefGoogle Scholar
  8. 8.
    Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106PubMedCrossRefGoogle Scholar
  9. 9.
    Chung CP, Avalos I, Raggi P, Stein CM (2007) Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 26:1228–1233PubMedCrossRefGoogle Scholar
  10. 10.
    Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873PubMedCrossRefGoogle Scholar
  11. 11.
    Van Doornum S, McColl G, Jenkins A et al (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80PubMedCrossRefGoogle Scholar
  12. 12.
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17PubMedCrossRefGoogle Scholar
  13. 13.
    Giles JT, Post W, Blumenthal RS et al (2006) Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329PubMedCrossRefGoogle Scholar
  14. 14.
    Warrington KJ, Kent PD, Frye RL et al (2005) Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 7:R984–R991PubMedCrossRefGoogle Scholar
  15. 15.
    Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30:1196–1202PubMedGoogle Scholar
  16. 16.
    Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES (2007) Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 25:102–111PubMedGoogle Scholar
  17. 17.
    Costenbader KH, Coblyn JS (2005) Statin therapy in rheumatoid arthritis. South Med J 98:534–540PubMedCrossRefGoogle Scholar
  18. 18.
    Arnaud C, Mach F (2006) Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 54:390–392PubMedCrossRefGoogle Scholar
  19. 19.
    Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  20. 20.
    Binder CJ, Chang MK, Shaw PX et al (2002) Innate and acquired immunity in atherogenesis. Nat Med 8:1218–1226PubMedCrossRefGoogle Scholar
  21. 21.
    Hansson GK, Holm J, Jonasson L (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135:169–175PubMedGoogle Scholar
  22. 22.
    Frostegard J, Ulfgren AK, Nyberg P et al (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33–43PubMedCrossRefGoogle Scholar
  23. 23.
    Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22:361–403PubMedCrossRefGoogle Scholar
  24. 24.
    Xu Q, Dietrich H, Steiner HJ et al (1992) Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 12:789–799PubMedGoogle Scholar
  25. 25.
    George J, Harats D, Gilburd B et al (2000) Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102:1822–1827PubMedGoogle Scholar
  26. 26.
    George J, Afek A, Gilburd B et al (1998) Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98:1108–1115PubMedGoogle Scholar
  27. 27.
    Mach F, Schonbeck U, Sukhova GK et al (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394:200–203PubMedCrossRefGoogle Scholar
  28. 28.
    Toubi E, Shoenfeld Y (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37:457–464PubMedCrossRefGoogle Scholar
  29. 29.
    Nicoletti A, Kaveri S, Caligiuri G et al (1998) Immunoglobulin treatment reduces atherosclerosis in Apo E knockout mice. J Clin Invest 102:910–918PubMedCrossRefGoogle Scholar
  30. 30.
    Robertson AK, Rudling M, Zhou X et al (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112:1342–1350PubMedCrossRefGoogle Scholar
  31. 31.
    Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRefGoogle Scholar
  32. 32.
    Arthritis Research Campaign. Arthritis: the big picture. http://www.arc.org.uk/arthinfo/bigpic.asp#6. Accessed 4 November 2007
  33. 33.
    Davenport G; Primary Care Rheumatology Society Steering Committee (2004) Rheumatology and musculoskeletal medicine. Br J Gen Pract 54:457–464PubMedGoogle Scholar
  34. 34.
    Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRefGoogle Scholar
  35. 35.
    Nicola PJ, Maradit-Kremers H, Roger VL et al (2005) The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52:412–420PubMedCrossRefGoogle Scholar
  36. 36.
    Snow MH, Mikuls TR (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17:234–241PubMedCrossRefGoogle Scholar
  37. 37.
    Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411PubMedCrossRefGoogle Scholar
  38. 38.
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24:445–451PubMedGoogle Scholar
  39. 39.
    del Rincon ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMedCrossRefGoogle Scholar
  40. 40.
    Jacobsson LT, Turesson C, Hanson RL et al (2001) Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 44:1170–1176PubMedCrossRefGoogle Scholar
  41. 41.
    Chung CP, Oeser A, Raggi P et al (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045–3053PubMedCrossRefGoogle Scholar
  42. 42.
    Park YB, Ahn CW, Choi HK et al (2003) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46:1714–1719CrossRefGoogle Scholar
  43. 43.
    Kumeda Y, Inaba M, Goto H et al (2002) Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46:1489–1497PubMedCrossRefGoogle Scholar
  44. 44.
    Daza L, Aguirre M, Jimenez M et al (2007) Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 26:533–537PubMedCrossRefGoogle Scholar
  45. 45.
    Nagata-Sakurai M, Inaba M, Goto H et al (2003) Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 48:3061–3067PubMedCrossRefGoogle Scholar
  46. 46.
    Roman MJ, Moeller E, Davis A et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144:249–256PubMedGoogle Scholar
  47. 47.
    Dessein PH, Joffe BI (2006) When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 33:201–203PubMedGoogle Scholar
  48. 48.
    Cederholm A, Svenungsson E, Jensen-Urstad K et al (2005) Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203PubMedGoogle Scholar
  49. 49.
    Swanberg M, Lidman O, Padyukov L et al (2005) MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 37:486–494PubMedCrossRefGoogle Scholar
  50. 50.
    Abeles AM, Pillinger MH (2006) Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393–407PubMedCrossRefGoogle Scholar
  51. 51.
    Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833–1846PubMedCrossRefGoogle Scholar
  52. 52.
    Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26:201–204PubMedCrossRefGoogle Scholar
  53. 53.
    Turesson C (2004) Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des 10:129–143PubMedCrossRefGoogle Scholar
  54. 54.
    Palinski W, Napoli C (2002) Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 22:1745–1750PubMedCrossRefGoogle Scholar
  55. 55.
    Choi M, Rolle S, Rane M et al (2003) Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 63:96–106PubMedCrossRefGoogle Scholar
  56. 56.
    Sadeghi MM, Tiglio A, Sadigh K et al (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71:1262–1268PubMedCrossRefGoogle Scholar
  57. 57.
    Kwak B, Mulhaupt F, Veillard N et al (2001) The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 131:41–46PubMedGoogle Scholar
  58. 58.
    Dolhain RJ, van der Heiden AN, ter Haar NT et al (1996) Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 39:1961–1969PubMedCrossRefGoogle Scholar
  59. 59.
    Nagashima T, Okazaki H, Yudoh K et al (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54:579–586PubMedCrossRefGoogle Scholar
  60. 60.
    McCarey DW, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRefGoogle Scholar
  61. 61.
    Hermann F, Forster A, Chenevard R et al (2005) Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45:461–464PubMedCrossRefGoogle Scholar
  62. 62.
    Ridker PM, Cushman M, Stampfer MJ et al (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRefGoogle Scholar
  63. 63.
    Ridker PM, Buring JE, Shih J et al (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMedGoogle Scholar
  64. 64.
    Koenig W, Sund M, Frohlich M et al (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237–242PubMedGoogle Scholar
  65. 65.
    Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565PubMedCrossRefGoogle Scholar
  66. 66.
    Pham T, Gossec L, Constantin A et al (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Jt Bone Spine 73:379–387CrossRefGoogle Scholar
  67. 67.
    McInnes IB, McCarey DW, Sattar N (2004) Do statins offer therapeutic potential in inflammatory arthritis. Ann Rheum Dis 63:1535–1537PubMedCrossRefGoogle Scholar
  68. 68.
    Sattar N, McInnes IB (2005) Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 17:286–292PubMedCrossRefGoogle Scholar
  69. 69.
    Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205–207PubMedCrossRefGoogle Scholar
  70. 70.
    Klareskog L, Hamsten A (2004) Statins in rheumatoid arthritis—two birds with one stone. Lancet 363:2011–2012PubMedCrossRefGoogle Scholar
  71. 71.
    Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423–1427PubMedCrossRefGoogle Scholar
  72. 72.
    Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116:408–416PubMedCrossRefGoogle Scholar
  73. 73.
    Kanda H, Hamasaki K, Kubo K et al (2002) Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 29:2024–2026PubMedGoogle Scholar
  74. 74.
    Abud-Mendoza C, de la Fuente H, Cuevas-Orta E et al (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607–611PubMedCrossRefGoogle Scholar
  75. 75.
    Van Doornum S, McColl G, Wicks IP (2004) Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 63:1571–1575PubMedCrossRefGoogle Scholar
  76. 76.
    Maki-Petaja KM, Booth AD, Hall FC et al (2007) Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50:852–858PubMedCrossRefGoogle Scholar
  77. 77.
    Okamoto H, Koizumi K, Kamitsuji S et al (2007) Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 34:964–968PubMedGoogle Scholar
  78. 78.
    Tikiz C, Utuk O, Pirildar T et al (2005) Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 32:2095–2101PubMedGoogle Scholar
  79. 79.
    Charles-Schoeman C, Khanna D, Furst DE et al (2007) Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34:1459–1464PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  1. 1.Department of Clinical Biochemistry (Vascular Disease Prevention Clinic)Royal Free HospitalLondonUK
  2. 2.Academic Department of SurgeryRoyal Free HospitalLondonUK

Personalised recommendations